PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Moderate Buy" from Analysts
MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation,
NASDAQ:PTCT